Evercore ISI Group Maintains Outperform on Ascendis Pharma, Raises Price Target to $329

Benzinga Newsdesk www.benzinga.com Positive 91.8%

Neg 0% Neu 0% Pos 91.8%

Evercore ISI Group analyst Josh Schimmer maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $324 to $329.